Skip to main content
Clinical Trials/EUCTR2012-004178-24-DE
EUCTR2012-004178-24-DE
Active, Not Recruiting
N/A

Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules - OsvaRen NEW

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hyperphosphataemia in end stage renal failure patients on extracorporeal renal replacement therapy
Sponsor
Fresenius Medical Care Deutschland GmbH
Status
Active, Not Recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 2, 2013
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Signed written informed consent form is obtained prior to starting the screening visit
  • Male and female patients 18–75 years of age with dialysis dependent renal failure (CKD 5D)
  • Patients have been on 3x/week in\-centre renal replacement therapy for at least 6 months on either high\-flux HD or OL\-/HDF
  • Prescribed haemodialysis session duration is \= 4 hours
  • spKt/V \= 1\.20 according to last in\-centre measurement prior the study enrolment
  • Patients have been on OsvaRen® tablets for at least 12 weeks as sole phosphate binder as sole phosphate binder and the titration phase has been completed according to physician´s discretion
  • Patients are able to take the study medication as prescribed particularly OsvaRen® granules (packed in stickpacks)
  • Patients are willing to stop any calcium, magnesium or vitamin D containing supplements
  • Patients are willing to maintain their typical diet with regards to phosphate uptake for the time of the study
  • Patients are willing to comply with the study protocol

Exclusion Criteria

  • Pregnant women (by blood ß\-hCG pregnancy test) or women breast\-feeding or unwilling to use contraceptive measures during the entire course of the study or
  • Patients with a life expectancy shorter than the planned duration of the study or
  • Patients with any acute or chronic severe disease potentially interfering with study outcomes or
  • Patients with PTH levels \> 800 ng/l or
  • Patients who participated in an interventional clinical study during the preceding 30 days or
  • Patients suffering from any other, not mentioned condition which could interfere with the patient’s ability to comply with the study or
  • Patients who previously participated in the same study

Outcomes

Primary Outcomes

Not specified

Similar Trials